Title
Process development for improved Car-t production utilizing an automated single use perfusion stirred-tank bioreactor
Conference Dates
March 20 – 23, 2022
Abstract
Ex vivo genetically-modified cellular immunotherapies, such as chimeric antigen receptor T-cells (CAR-T), have generated significant clinical and commercial outcomes due to their unparalleled response rates against refractory/relapsed blood cancers. However, the development and manufacture of these advanced therapies face a number of translational bottlenecks that must be addressed to ensure long-term commercial viability.
The cost and variability associated with these personalized advanced therapies presents a critical manufacturing and translational challenge. Due to the nature of cell therapies, single-use technologies are typically used for their production. This work demonstrates the importance of determining critical manufacturing process parameters using single-use technologies and incorporating automation into the process. The work builds off of previous proof of concept work completed in the group for the production of CAR-T cells in automated, stirred tank, single-use ambr250® bioreactors. These follow-on experiments utilize concepts of quality by design and design of experiments (DoE) to systematically determine the impact of process parameters on CAR-T production.
Please click Additional Files below to see the full abstract.
Recommended Citation
Tiffany Hood, Fern Slingby, Quentin Vicard, Nicola Bevan, Viktor Sander, Winfried Geis, and Qasim A. Rafiq, "Process development for improved Car-t production utilizing an automated single use perfusion stirred-tank bioreactor" in "Single-Use Technologies V: Building The Future", Magali Barbaroux, Sartorius, France; Martina Micheletti, University College London, UK Eds, ECI Symposium Series, (2022). https://dc.engconfintl.org/sut_v/42